Table 1 Baseline demographic and clinical characteristics of treated patients
Characteristic | N + S (N = 33) | N + P (N = 20) |
|---|---|---|
Age, years | ||
 Median (range) | 57.0 (38–75) | 56.0 (40–72) |
Age <65 years, n (%) | 24 (72.7) | 17 (85.0) |
Sex, n (%) | ||
 Male | 26 (78.8) | 18 (90.0) |
 Female | 7 (21.2) | 2 (10.0) |
Race, n (%) | ||
 Caucasian | 28 (84.8) | 18 (90.0) |
 Asian | 1 (3.0) | 0 |
 Black/African American | 2 (6.1) | 1 (5.0) |
 Other | 2 (6.1) | 1 (5.0) |
Ethnicity, n (%) | ||
 Hispanic/Latino | 2 (6.1) | 0 |
 Not Hispanic/Latino | 29 (87.9) | 18 (90.0) |
 Not reported | 2 (6.1) | 2 (10.0) |
MSKCC risk category, n (%) | ||
 Favorable | 16 (48.5) | 4 (20.0) |
 Intermediate | 16 (48.5) | 14 (70.0) |
 Poor | 1 (3.0) | 2 (10.0) |
Prior surgery, n (%) | 33 (100.0) | 20 (100.0) |
Prior radiotherapy, n (%) | 5 (15.2) | 10 (50.0) |
Prior systemic therapy, n (%) | 14 (42.4) | 20 (100.0) |
 VEGFR inhibitor | 5 (15.2) | 17 (85.0) |
 Other antiangiogenic | 7 (21.2) | 17 (85.0) |
 Cytokine | 9 (27.3) | 10 (50.0) |
 mTOR inhibitor | 0 | 3 (15.0) |
 Other | 3 (9.1) | 4 (20.0) |
No. of prior therapies, n (%) | ||
 0 | 19 (57.6) | 0 |
 1 | 14 (42.4) | 14 (70.0) |
 2 | 0 | 4 (20.0) |
 3 | 0 | 1 (5.0) |
  ≥4 | 0 | 1 (5.0) |
Treatment setting, a n (%) | ||
 Adjuvant | 3 (9.1) | 4 (20.0) |
 Metastatic | 0 | 2 (10.0) |
 Neoadjuvant | 11 (33.3) | 16 (80.0) |